Physician profile
Eric Shieh
NPI 1932581642
$7,478.27
in general payments reported to CMS, 2019-2025
26 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $414 · 2021: $763 · 2022: $1,137 · 2023: $1,741 · 2024: $1,089 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,728 · Long Term Medical Supply Or Device Loan: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,728.39 |
| Long Term Medical Supply Or Device Loan | $360.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $925.20 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Abbvie INC. | $761.23 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $669.57 | 2021-2025 | Cequa, Xelpros, Bromsite |
| Bausch & Lomb Americas INC. | $602.19 | 2022-2025 | Miebo, Vyzulta, Alrex |
| Carl Zeiss Meditec USA, INC. | $587.42 | 2023 | Lumera 700, Visumax, Iolmaster 700 |
| Oyster Point Pharma, INC. | $486.45 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $454.60 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $424.35 | 2019-2023 | |
| Amgen INC. | $358.91 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $357.32 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $287.99 | 2019-2021 | |
| Biotissue Holdings INC. | $282.92 | 2020-2024 | |
| Kala Pharmaceuticals, INC. | $234.93 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $213.60 | 2020-2022 | |
| Glaukos Corporation | $165.64 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $148.75 | 2021-2024 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $115.39 | 2020-2021 | |
| Horizon Therapeutics Plc | $98.43 | 2023 | Tepezza |
| Thea Pharma INC. | $88.94 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $49.97 | 2022-2024 | Oxervate |
| Rxsight INC | $46.79 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Ivantis, INC | $45.15 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $28.76 | 2024 | Acthar |
| Omeros Corporation | $19.01 | 2019 | |
| Integra Lifesciences Corporation | $15.63 | 2019 | |
| New World Medical,INC. | $9.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.